Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locoregionally Recurrent Hormone-receptor Positive Breast Cancer”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Looking for participantsNCT07121244
What this trial is testing

68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer
Radionetics Oncology 62
Early research (Phase 1)Looking for participantsNCT06745804
What this trial is testing

Study of 68Ga-R10602

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast CancerHormone Receptor Positive Breast Adenocarcinoma
Radionetics Oncology 36
Not applicableLooking for participantsNCT05795335
What this trial is testing

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
RenJi Hospital 172
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Large-scale testing (Phase 3)Active Not RecruitingNCT02763566
What this trial is testing

Abemaciclib (LY2835219) in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 463